Efficacy of adjunctive aripiprazole in major depressive disorder: A pooled response quartile analysis and the predictive value of week 2 early response

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 14, Issue 3, 2012, Pages

  Casey, Daniel E ^a   Laubmeier, Kimberly K ^b   Marler, Sabrina Vogel ^b   Forbes, Robert A ^c   Baker, Ross A ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; PLACEBO;

ADJUVANT THERAPY; ADULT; AGED; AKATHISIA; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; REMISSION; RESTLESSNESS; RISK ASSESSMENT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 84864651737     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.11m01251     Document Type: Article

References (25)

1. Qaseem A, Snow V, Denberg T, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149(10):725-733. PubMed
2. Nakajima S, Suzuki T, Watanabe K, et al. Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):259-264. PubMed doi:10.1016/j.pnpbp.2009.12.001 Show Abstract Show Abstract
3. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Am J Psychiatry. 2010;167(10):A34. doi:10.1176/appi.ajp.2010.167.10.a34
4. Nutt DJ, Davidson JR, Gelenberg AJ, et al. International consensus statement on major depressive disorder. J Clin Psychiatry. 2010;71 (suppl E1):e08. PubMed
5. Tohen M, Case M, Trivedi MH, et al. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry. 2010;71(4):451-462. PubMed doi:10.4088/JCP.08m04984gre Show Abstract Show Abstract
6. Muzina DJ, Chambers JS, Camacho TA, et al. Adjunctive aripiprazole for depression: predictive value of early assessment. Am J Manag Care. 2011;17:793-801.
7. Gelenberg AJ, Chesen CL. How fast are antidepressants? J Clin Psychiatry. 2000;61(10):712-721. PubMed doi:10.4088/JCP.v61n1002 Show Abstract Show Abstract
8. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. PubMed doi:10.1192/bjp.134.4.382 Show Abstract Show Abstract
9. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197-206. PubMed Show Abstract Show Abstract
10. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853. PubMed doi:10.4088/JCP.v68n0604 Show Abstract Show Abstract
11. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165. PubMed doi:10.1097/JCP.0b013e31816774f9 Show Abstract Show Abstract
12. Chandler GM, Iosifescu DV, Pollack MH, et al. RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322-325. doi: 10.1111/j.1755-5949.2009.00102.x PubMed
13. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179-200. PubMed doi:10.1016/S0193-953X(05)70283-5 Show Abstract Show Abstract
14. Mallinckrodt CH, Raskin J, Wohlreich MM, et al. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC Psychiatry. 2004;4(1):26. PubMed doi:10.1186/1471-244X-4-26 Show Abstract Show Abstract
15. Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol. 2010;25(4):189-198. PubMed doi:10.1097/YIC.0b013e328330adb2 Show Abstract Show Abstract
16. Millan MJ, Gobert A, Rivet J-M, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000;12(3):1079-1095. PubMed doi:10.1046/j.1460-9568.2000.00982.x Show Abstract Show Abstract
17. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381-389. PubMed doi:10.1124/jpet.102.033175 Show Abstract Show Abstract
18. Tadori Y, Forbes RA, McQuade RD, et al. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol. 2008;597(1-3):27-33. PubMed doi:10.1016/j.ejphar.2008.09.008 Show Abstract Show Abstract
19. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400-1411. PubMed doi:10.1038/sj.npp.1300203 Show Abstract Show Abstract
20. Chernoloz O, El Mansari M, Blier P. Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology (Berl). 2009;206(2):335-344. PubMed doi:10.1007/s00213-009-1611-7 Show Abstract Show Abstract
21. Nelson JC, Thase ME, Trivedi MH, et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (Studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry. 2009;11(6):344-352. PubMed doi:10.4088/PCC.08m00744gre Show Abstract Show Abstract
22. Fava M, Wisniewski SR, Thase ME, et al. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. J Clin Psychopharmacol. 2009;29(4):362-367. PubMed doi:10.1097/JCP.0b013e3181ac9b0b Show Abstract Show Abstract
23. Berman RM, Thase ME, Trivedi MH, et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat. 2011;7:303-312. PubMed doi:10.2147/NDT.S18333 Show Abstract Show Abstract
24. Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 2008;117(4):253-259. PubMed doi:10.1111/j.1600-0447.2007.01130.x Show Abstract Show Abstract
25. Berman R, Thase M, Trivedi M, et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat. 2011;7:303-312.